63 related articles for article (PubMed ID: 19675589)
1. Multitargeted tyrosine kinase inhibitor stimulates expression of IL-6 and activates JAK2/STAT5 signaling in acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Yokoyama A
Leukemia; 2009 Dec; 23(12):2304-8. PubMed ID: 19675589
[No Abstract] [Full Text] [Related]
2. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
3. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
4. Src transduces signaling via growth hormone (GH)-activated GH receptor (GHR) tyrosine-phosphorylating GHR and STAT5 in human leukemia cells.
Manabe N; Kubota Y; Kitanaka A; Ohnishi H; Taminato T; Tanaka T
Leuk Res; 2006 Nov; 30(11):1391-8. PubMed ID: 16650892
[TBL] [Abstract][Full Text] [Related]
5. Stem cell factor synergistically enhances thrombopoietin-induced STAT5 signaling in megakaryocyte progenitors through JAK2 and Src kinase.
Drayer AL; Boer AK; Los EL; Esselink MT; Vellenga E
Stem Cells; 2005 Feb; 23(2):240-51. PubMed ID: 15671147
[TBL] [Abstract][Full Text] [Related]
6. A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination.
Kapuria V; Levitzki A; Bornmann WG; Maxwell D; Priebe W; Sorenson RJ; Showalter HD; Talpaz M; Donato NJ
Cell Signal; 2011 Dec; 23(12):2076-85. PubMed ID: 21855629
[TBL] [Abstract][Full Text] [Related]
7. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.
Ferrajoli A; Faderl S; Van Q; Koch P; Harris D; Liu Z; Hazan-Halevy I; Wang Y; Kantarjian HM; Priebe W; Estrov Z
Cancer Res; 2007 Dec; 67(23):11291-9. PubMed ID: 18056455
[TBL] [Abstract][Full Text] [Related]
8. Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway.
Okutani Y; Kitanaka A; Tanaka T; Kamano H; Ohnishi H; Kubota Y; Ishida T; Takahara J
Oncogene; 2001 Oct; 20(45):6643-50. PubMed ID: 11641791
[TBL] [Abstract][Full Text] [Related]
9. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
[TBL] [Abstract][Full Text] [Related]
10. Imatinib effect on growth and signal transduction in polycythemia vera.
Gaikwad A; Verstovsek S; Yoon D; Chang KT; Manshouri T; Nussenzveig R; Cortes J; Vainchenker W; Prchal JT
Exp Hematol; 2007 Jun; 35(6):931-8. PubMed ID: 17533047
[TBL] [Abstract][Full Text] [Related]
11. Janus kinase-signal transducer and activator of transcription mediates phosphatidic acid-induced interleukin (IL)-1beta and IL-6 production.
Lee C; Lim HK; Sakong J; Lee YS; Kim JR; Baek SH
Mol Pharmacol; 2006 Mar; 69(3):1041-7. PubMed ID: 16354768
[TBL] [Abstract][Full Text] [Related]
12. Signaling through JAK2-STAT5 pathway is essential for IL-3-induced activation of microglia.
Natarajan C; Sriram S; Muthian G; Bright JJ
Glia; 2004 Jan; 45(2):188-96. PubMed ID: 14730712
[TBL] [Abstract][Full Text] [Related]
13. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
14. Induction of differentiation by IL-6-type cytokines is impaired in myeloid leukaemia cells unable to activate Stat5a.
Piekorz RP; Hocke GM
Cytokine; 1997 Sep; 9(9):639-49. PubMed ID: 9325012
[TBL] [Abstract][Full Text] [Related]
15. RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells.
Futami M; Hatano T; Soda Y; Kobayashi S; Miyagishi M; Tojo A
Leukemia; 2008 Jun; 22(6):1131-8. PubMed ID: 18368071
[TBL] [Abstract][Full Text] [Related]
16. JAK2V617F/STAT5 signaling pathway promotes cell proliferation through activation of Pituitary Tumor Transforming Gene 1 expression.
Shen XL; Wei W; Xu HL; Zhang MX; Qin XQ; Shi WZ; Jiang ZP; Chen YJ; Chen FP
Biochem Biophys Res Commun; 2010 Aug; 398(4):707-12. PubMed ID: 20621061
[TBL] [Abstract][Full Text] [Related]
17. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
Chai SK; Nichols GL; Rothman P
J Immunol; 1997 Nov; 159(10):4720-8. PubMed ID: 9366395
[TBL] [Abstract][Full Text] [Related]
18. MSK1 activation in acute myeloid leukemia cells with FLT3 mutations.
Odgerel T; Kikuchi J; Wada T; Shimizu R; Kano Y; Furukawa Y
Leukemia; 2010 May; 24(5):1087-90. PubMed ID: 20357825
[No Abstract] [Full Text] [Related]
19. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response.
Wang LH; Kirken RA; Erwin RA; Yu CR; Farrar WL
J Immunol; 1999 Apr; 162(7):3897-904. PubMed ID: 10201908
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II activates Stat5 through Jak2 kinase in cardiac myocytes.
McWhinney CD; Dostal D; Baker K
J Mol Cell Cardiol; 1998 Apr; 30(4):751-61. PubMed ID: 9602424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
